Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RNA-targeting and gene editing therapies for transthyretin amyloidosis

23 Mar 2022

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloidosis: Diagnosis, Treatment, Outcomes
Share to Cardiomyopathy and Myosin Studies
Share to Eosinophilic Disorders and Syndromes

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 35322226
DOI: 10.1038/s41569-022-00683-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RNA-targeting and gene editing therapies for transthyretin amyloidosisPMID 35322226Read ↗

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin AmyloidosisSemantic proximity Read ↗

RNA Targeting and Gene Editing Strategies for Transthyretin AmyloidosisSemantic proximity Read ↗

Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathySemantic proximity Read ↗

Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter FutureSemantic proximity Read ↗

Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatmentsSemantic proximity Read ↗

Advances in RNA Therapeutics: Classes, Innovations and Clinical ApplicationsSemantic proximity Read ↗

Gene therapy: lessons learned from liver transplantation for transthyretin-amyloidosis.Semantic proximity Read ↗

Treating hereditary transthyretin amyloidosis: Present & future challenges.Semantic proximity Read ↗

Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.Semantic proximity Read ↗

Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisSemantic proximity Read ↗

Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin AmyloidosisSemantic proximity Read ↗

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin AmyloidosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.